RECOVERY & TISSUE REPAIR RESEARCH / FAQ
Questions From the Study Record
Direct, citation-anchored answers to the questions readers most often bring to GLOW, KPV, and TB-500.
What is GLOW peptide?
GLOW is not a single peptide but a combination product — typically GHK-Cu (a copper-tripeptide), BPC-157 (a gastric-derived repair peptide), and TB-500 (an actin-binding fragment of thymosin beta-4) — sold together as a research-use blend aimed at skin and tissue repair. No study has tested the three-peptide combination itself; every claim about GLOW is extrapolated from studies of its individual ingredients [1][3][4]. It is not FDA-approved, and because it contains TB-500 (a WADA-prohibited substance), it carries anti-doping implications regardless of its skin-focused marketing.
What does the GLOW peptide do?
Each GLOW ingredient is studied for a different repair function: GHK-Cu stimulates dermal fibroblasts to synthesize collagen, elastin, and glycosaminoglycans [4][5]; BPC-157 promotes new blood-vessel growth by activating the VEGFR2-Akt-eNOS pathway [3]; and TB-500 (via its parent protein) is associated with faster cell migration and reduced scarring. Combined, the thesis is matrix-building plus vascular support plus faster cell movement — a mechanistically coherent story, but one that has never been tested as a combined intervention in a published trial.
What does GLOW peptide have in it?
Most commercial GLOW formulations contain three peptides: GHK-Cu (glycyl-L-histidyl-L-lysine copper complex, approximately 402.9 Da), BPC-157 (a 15-residue synthetic peptide, approximately 1419 Da), and TB-500 (the 7-residue fragment Ac-LKKTETQ, approximately 889 Da). A commonly cited research-label ratio is 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial, but this ratio is a market convention, not a value validated in any controlled study — exact ratios and purity vary by supplier and are not independently verified.
What peptides are in the GLOW blend?
The three constituent peptides are GHK-Cu, BPC-157, and TB-500. GHK-Cu is a naturally occurring human tripeptide (declining with age) complexed with copper to drive matrix synthesis [4]. BPC-157 is derived from a gastric protective protein and is studied for angiogenesis and cytoprotection [2][3]. TB-500 is a synthetic fragment of thymosin beta-4 studied — mostly via the full-length parent protein — for cell migration and wound repair. See the dedicated pages for GLOW and TB-500 for the full evidence behind each.
What is KPV peptide?
KPV is a three-amino-acid peptide (lysine-proline-valine, C16H30N4O4) corresponding to the C-terminal three residues of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains alpha-MSH's anti-inflammatory activity without the parent hormone's pigment-darkening effect [10]. Nearly all published research on KPV studies its effect in the gut, using rodent colitis models and human intestinal cell lines; no published human clinical trial of KPV exists [6][7][8][9].
What does KPV peptide do?
In preclinical models, KPV is taken up directly into intestinal epithelial cells by the PepT1 transporter — which is upregulated in inflamed gut tissue — and at nanomolar concentrations suppresses NF-kB and MAP-kinase inflammatory signaling, reducing pro-inflammatory cytokine output [8]. In mouse colitis models, this translates to earlier recovery, lower myeloperoxidase activity, and reduced inflammatory cell infiltration, an effect that persists even without the classic melanocortin-1 receptor [9].
What is KPV peptide used for?
In published research, KPV is used almost exclusively to study gut-mucosal inflammation — models of DSS- and TNBS-induced colitis in mice, and inflamed human intestinal cell lines in vitro [6][7][8][9]. Because free KPV breaks down quickly in biological fluids, a large share of recent work focuses on delivery formulations (nanoparticles, hydrogels) designed to keep it intact at the site of inflammation [6][7]. There is no published human-use indication for KPV.
What is KPV peptide good for?
Based on the cited literature, KPV's demonstrated effect is calming gut-mucosal inflammation in animal models — reducing cytokine signaling, myeloperoxidase activity, and inflammatory infiltrate in colitis [8][9]. That is the only indication with direct experimental support. Claims that extend KPV's use to skin, general wellness, or broad anti-inflammatory benefit in people go beyond what the current, entirely preclinical evidence supports.
What is TB-500?
TB-500 is a synthetic, N-acetylated 7-amino-acid fragment (Ac-LKKTETQ) corresponding to residues 17-23 of thymosin beta-4, a 43-amino-acid protein that binds and buffers actin, the cell's cytoskeletal building block. Most published efficacy studies — wound healing, cardiac repair, stroke recovery — used the full-length protein, not the isolated 7-residue fragment sold commercially as TB-500 [12][14].
What does TB-500 stand for and what does TB stand for in TB-500?
"TB" in TB-500 refers to thymosin beta — the protein family TB-500 is derived from (specifically thymosin beta-4). The "500" is a supplier-assigned product designation rather than a standard chemical or scientific numbering; it does not correspond to a molecular weight, dose, or any measured value in the cited literature. In veterinary contexts the same fragment is sometimes called TB1000.
What is TB-500 used for in research?
In published research, TB-500's parent protein (full-length thymosin beta-4) has been studied for wound re-epithelialization — 42% faster at 4 days, 61% faster at 7 days, in a rat model [16] — post-coronary-ligation cardiac repair via PINCH-ILK-Akt signaling [15], and neurological recovery after simulated stroke in rats, effective at 2 and 12 mg/kg but not at 18 mg/kg [11]. One completed human trial exists: a Phase 1 IV safety study in 40 healthy volunteers, using the full-length protein, well tolerated up to 1260 mg [13].
Does TB-500 work for muscle tears and recovery from exercise?
No controlled human trial has tested TB-500, or its full-length parent protein, for muscle-tear or exercise-recovery outcomes specifically. The cited animal literature covers dermal wounds, cardiac tissue, and cerebral ischemia rather than musculoskeletal exercise injury [11][15][16]. Research-community reports describing faster recovery from tendon, ligament, or muscle injuries are widespread but are anecdotal — not from a controlled study — and a 2026 review of this compound class notes that rigorous human safety and efficacy data remain scarce [1].